Version
Year
Key Notes
PDUFA I
1992
Original enactment; established pharmaceutical user fees to fund FDA drug reviews.
PDUFA II
1997
First reauthorization; extended user fee structure.
PDUFA III
2002
Second reauthorization; added risk management and drug safety provisions.
PDUFA IVNo
2007
Sanders voted against: sought drug reimportation from Canada and curtailment of direct-to-consumer advertising.
PDUFA VNo
2012
Sanders voted against: said the bill perpetuated a system making Americans pay far more for medicines than people anywhere else.
PDUFA VINo
2017
Sanders voted against: again the sole senator to oppose the bipartisan committee package.
PDUFA VIIYes
2022
Sanders voted in favor. Included tighter FDA oversight of accelerated approval pathway, clinical trial diversity mandates, and greater leeway for unannounced foreign site inspections.